Loading clinical trials...

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

NCT00742131•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,
•ECOG performance status of \</= 2.
•Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,
•Negative pregnancy test.

Exclusion Criteria

•Chemotherapy within 4-6 weeks of the start of treatment,
•Radiotherapy within 4 weeks of the start of treatment,
•Known brain metastasis,
•Uncontrolled medical disorder such as infection or cardiovascular disease,
•HIV positive,
•Pregnant or breastfeeding women

Key Dates

Start Date

March 17, 2005

Primary Completion Date

May 13, 2008

Completion Date

August 29, 2011

Last Updated

July 31, 2017

Enrollment

ACTUAL participants

Conditions

Solid Tumours

Interventions

GSK1363089

DRUG

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

NCT07403370

Solid TumoursOlanzapine+1 more

View study

RECRUITINGPHASE1

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

NCT06815575

Solid TumoursAdvanced Solid Tumours

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Inclusion Criteria

Exclusion Criteria

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours